Skip to main content

Subphenotype-Dependent Benefits of Bariatric Surgery for Individuals at Risk for Type 2 Diabetes.

Diabetes care2025-04-11PubMed
Total: 80.0Innovation: 8Impact: 8Rigor: 8Citation: 8

Summary

Across discovery and replication bariatric cohorts, relative weight loss was similar among Tübingen subphenotypes, but high-risk Cluster 5 experienced the largest improvements in insulin resistance, β-cell function, and the highest prediabetes remission rates. High-risk individuals often shifted to lower-risk clusters after surgery, an effect not seen in lifestyle controls.

Key Findings

  • Relative weight loss was similar across clusters, but insulin resistance reduction and β-cell function improvement were strongest in Cluster 5.
  • Prediabetes remission was lowest in low-risk Cluster 4 and highest in high-risk Cluster 5.
  • High-risk clusters shifted to lower-risk clusters after bariatric surgery in both cohorts, but not in the lifestyle control cohort.

Clinical Implications

Use metabolic clustering (e.g., Tübingen Clusters) to identify high-risk individuals (C5) most likely to derive insulin resistance and β-cell benefits and achieve prediabetes remission after bariatric surgery. Incorporate subphenotyping into preoperative evaluation and shared decision-making.

Why It Matters

This study operationalizes precision metabolic surgery by linking subphenotypes to differential metabolic benefit and remission, with replication across centers. It can change surgical eligibility and counseling for at-risk individuals before T2D onset.

Limitations

  • Observational design without randomization may allow residual confounding
  • Follow-up duration and long-term hard outcomes (e.g., incident T2D) not detailed in the abstract

Future Directions

Prospective randomized or pragmatic trials stratified by metabolic clusters to test surgery versus medical/lifestyle therapy on incident T2D and cardiovascular outcomes; development of clinically deployable clustering tools.

Study Information

Study Type
Cohort
Research Domain
Treatment
Evidence Level
II - Multicenter observational cohorts with independent replication and a matched behavioral control group.
Study Design
OTHER